
Granules India Limited has informed the Exchange regarding a press release dated January 30, 2025, titled "Granules Strengthens ADHD Portfolio with FDA Approval for Lisdexamfetamine Dimesylate Capsules".
Filed with NSE ·

Granules India Limited has informed the Exchange regarding a press release dated January 30, 2025, titled "Granules Strengthens ADHD Portfolio with FDA Approval for Lisdexamfetamine Dimesylate Capsules".
6ix hasn’t read this filing yet.
Follow Granules India into a list and get an email when it puts out news.
Follow Granules India